贝伐珠单抗一线治疗晚期卵巢癌的最佳治疗时长:AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 开放标签随机III期试验
该多中心开放标签随机III期试验比较贝伐珠单抗联合一线化疗标准时长(15个月)与延长时长(30个月)治疗新诊断IIB-IV期卵巢癌的疗效。927例患者随机1:1分组,主要终点无进展生存期(PFS)两组无差异(HR 0.99,95%CI 0.85-1.15,P=0.90),总生存期(OS)亦无差异(HR 1.04,95%CI 0.87-1.23,P=0.68)。结论为延长贝伐珠单抗至30个月未改善PFS或OS,15个月仍为标准治疗。
要点
- 贝伐珠单抗15个月与30个月组中位PFS分别为24.2个月与26.0个月,无显著差异(HR 0.99,95%CI 0.85-1.15,P=0.90)。
- 两组OS无差异(HR 1.04,95%CI 0.87-1.23,P=0.68),延长治疗未带来生存获益。
- 标准组与试验组特别关注的不良事件发生率分别为29%与34%,与贝伐珠单抗已知安全性一致。
核心结论
- 延长贝伐珠单抗治疗至30个月未改善初治上皮性卵巢癌、输卵管癌或腹膜癌患者的PFS或OS,15个月治疗时长仍为标准治疗。
研究设计与样本
- 多中心、开放标签、随机III期试验(ClinicalTrials.gov标识NCT01462890),纳入新诊断FIGO IIB-IV期上皮性卵巢癌、输卵管癌或腹膜癌患者。
- 患者接受初次肿瘤细胞减灭术后行6周期化疗(紫杉醇175 mg/m2联合卡铂曲线下面积5,每3周一次)及贝伐珠单抗(15 mg/kg,每3周一次)。
- 患者按1:1随机分配接受贝伐珠单抗15个月或30个月治疗,按FIGO分期/残留肿瘤分层。
- 主要终点为研究者根据RECIST 1.1评估的PFS;次要终点包括OS、安全性和耐受性。
- 2011年11月11日至2013年8月6日期间共927例女性随机分组。
主要发现
- 两组PFS无差异(HR 0.99,95%CI 0.85-1.15,非分层log-rank P=0.90)。
- 标准时长组与延长时长组中位PFS分别为24.2个月与26.0个月;限制性平均PFS分别为39.5个月与39.3个月。
- 两组OS无差异(HR 1.04,95%CI 0.87-1.23,P=0.68)。
- 标准组与试验组特别关注的不良事件(严重/非严重)发生率分别为29%与34%,与标准贝伐珠单抗已知安全性特征一致。
关键数值与推荐
- 贝伐珠单抗15个月组与30个月组中位PFS分别为24.2个月与26.0个月(HR 0.99,95%CI 0.85-1.15,P=0.90)。
- 贝伐珠单抗15个月组与30个月组限制性平均PFS分别为39.5个月与39.3个月。
- 贝伐珠单抗15个月组与30个月组OS的HR为1.04(95%CI 0.87-1.23,P=0.68)。
- 贝伐珠单抗15个月组与30个月组特别关注的不良事件发生率分别为29%与34%。
临床怎么用
- 对于新诊断上皮性卵巢癌、输卵管癌或腹膜癌患者,贝伐珠单抗治疗时长15个月仍为标准治疗。
- 延长贝伐珠单抗治疗至30个月未改善PFS或OS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV ovarian cancer. METHODS: In this multicenter, open-label, randomized phase III trial (ClinicalTrials.gov identifier: NCT01462890), patients with newly diagnosed International Federation of Gynecology and Obstetrics stage IIB-IV epithelial ovarian, fallopian tube, or peritoneal cancer underwent primary cytoreductive surgery followed by six cycles of chemotherapy (paclitaxel 175 mg/m2 plus carboplatin area under the curve 5 once every 3 weeks) and bevacizumab (15 mg/kg once every 3 weeks). Patients were randomly assigned 1:1 to receive bevacizumab for either 15 or 30 months, stratified by International Federation of Gynecology and Obstetrics stage/residual tumor. The primary end point was investigator-assessed progression-free survival (PFS) according to RECIST version 1.1. Secondary end points included overall survival (OS), safety, and tolerability. RESULTS: Between November 11, 2011, and August 6, 2013, 927 women were randomly assigned. There was no difference in PFS between treatment arms (hazard ratio, 0.99; 95% CI, 0.85 to 1.15; unstratified log-rank P = .90). Median PFS was 24.2 versus 26.0 months with standard versus extended duration of bevacizumab, respectively; restricted mean PFS was 39.5 versus 39.3 months, respectively. There was no OS difference between treatment arms (hazard ratio, 1.04; 95% CI, 0.87 to 1.23; P = .68). Serious/nonserious adverse events of special interest occurred in 29% versus 34% of patients in the standard versus experimental arms, respectively, and were consistent with the known safety profile of standard bevacizumab. CONCLUSION: Longer treatment duration with bevacizumab for up to 30 months did not improve PFS or OS in patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer. A bevacizumab treatment duration of 15 months remains the standard of care.
引用
- Pfisterer J, Joly F, Kristensen G, et al. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol. 2022. PMID: 36332161. doi:10.1200/JCO.22.01010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。